MA26700A1 - FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. - Google Patents

FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.

Info

Publication number
MA26700A1
MA26700A1 MA25820A MA25820A MA26700A1 MA 26700 A1 MA26700 A1 MA 26700A1 MA 25820 A MA25820 A MA 25820A MA 25820 A MA25820 A MA 25820A MA 26700 A1 MA26700 A1 MA 26700A1
Authority
MA
Morocco
Prior art keywords
inhibitors
preparation
controlled release
pharmaceutical formulations
pde
Prior art date
Application number
MA25820A
Other languages
English (en)
Inventor
King Elizabeth
James Macrae Ross
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26700(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of MA26700A1 publication Critical patent/MA26700A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT Société dite : PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. REVENDICATION DE PRIORITES GB 23/10/1998 9823192.1 GB 27/10/1998 9826392.4 GB 16/11/1998 9825117.6 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulations pharmaceutiques d'inhibiteurs de PDE-5 de GMPc à libération contrôlée,et procédé pour leur préparation L'invention concerne des formulations à libération contrôlée contenant un inhibiteur de PDE-5 de GMPc, pour l'administration orale. Elle concerne également un procédé pour leur préparation. Application : utilisation de ces formulations dans le traitement ou la prévention d'un dysfonctionnement sexuel.
MA25820A 1998-10-23 1999-10-20 FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION. MA26700A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MA26700A1 true MA26700A1 (fr) 2004-12-20

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25820A MA26700A1 (fr) 1998-10-23 1999-10-20 FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.

Country Status (44)

Country Link
US (1) US6964780B1 (fr)
EP (1) EP1123088B1 (fr)
JP (1) JP2002528408A (fr)
KR (1) KR20010075659A (fr)
CN (1) CN1324233A (fr)
AP (1) AP2001002125A0 (fr)
AT (1) ATE340562T1 (fr)
AU (1) AU756509B2 (fr)
BG (1) BG65323B1 (fr)
BR (1) BR9914718A (fr)
CA (1) CA2348086C (fr)
CO (1) CO5160262A1 (fr)
CR (1) CR6326A (fr)
CY (1) CY1106239T1 (fr)
CZ (1) CZ20011427A3 (fr)
DE (1) DE69933383T2 (fr)
DK (1) DK1123088T3 (fr)
DZ (1) DZ2923A1 (fr)
EA (1) EA004068B1 (fr)
EE (1) EE200100235A (fr)
ES (1) ES2272082T3 (fr)
GT (1) GT199900184A (fr)
HK (1) HK1041818A1 (fr)
HR (1) HRP20010285A2 (fr)
HU (1) HUP0104318A3 (fr)
ID (1) ID28232A (fr)
IL (1) IL141764A (fr)
IS (1) IS5865A (fr)
MA (1) MA26700A1 (fr)
MX (1) MXPA01004011A (fr)
MY (1) MY130727A (fr)
NO (1) NO20011933L (fr)
NZ (1) NZ510275A (fr)
OA (1) OA11664A (fr)
PA (1) PA8484301A1 (fr)
PE (1) PE20001286A1 (fr)
PL (1) PL195789B1 (fr)
PT (1) PT1123088E (fr)
SK (1) SK286473B6 (fr)
TR (1) TR200101103T2 (fr)
TW (1) TW577756B (fr)
UA (1) UA67802C2 (fr)
UY (1) UY25765A1 (fr)
WO (1) WO2000024383A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504436A (en) * 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
JP4806507B2 (ja) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． 制御放出ヒドロコドン処方
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA03001958A (es) 2000-09-06 2003-06-24 Tanabe Seiyaku Co Preparaciones para administrar oral.
CN101653411A (zh) 2000-10-30 2010-02-24 欧罗赛铁克股份有限公司 控释氢可酮制剂
JP4179784B2 (ja) * 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1896076A2 (fr) * 2005-06-27 2008-03-12 Daniel Drai Compositions et methodes permettant d'ameliorer la fonction sexuelle
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
CA2626134C (fr) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
EP1790343A1 (fr) * 2005-11-11 2007-05-30 Emotional Brain B.V. Compositions pharmaceutiques et leur utilisation pour le traitement des dysfonctions sexuelles chez la femme
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CA2660476C (fr) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations de flibanserine et leur procede de fabrication
EP2056797A2 (fr) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Système de libération contrôlée et procédé de préparation correspondant
EP1925307A1 (fr) 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
WO2008115797A1 (fr) * 2007-03-16 2008-09-25 Pavo, Inc. Compositions thérapeutiques et procédés associés
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009098697A1 (fr) * 2008-02-08 2009-08-13 Dexxon Ltd. Formes pharmaceutiques de modafinil et de sildénafil
EP2374460A4 (fr) 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv Composition de sildénafil à libération pulsée et son procédé de préparation
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
US20140328911A1 (en) * 2011-07-22 2014-11-06 Pom Wonderful. Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (fr) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1997048382A2 (fr) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Preparation medicamenteuse d'action prolongee, de type a plusieurs unites
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE69721559T2 (de) * 1997-01-06 2003-11-27 Pfizer Inc., New York Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
BR9914718A (pt) 2001-07-10
ES2272082T3 (es) 2007-04-16
PL347476A1 (en) 2002-04-08
IL141764A0 (en) 2002-03-10
GT199900184A (es) 2001-04-14
DZ2923A1 (fr) 2004-03-01
WO2000024383A1 (fr) 2000-05-04
CA2348086C (fr) 2007-01-23
AU756509B2 (en) 2003-01-16
ATE340562T1 (de) 2006-10-15
IL141764A (en) 2008-06-05
BG65323B1 (bg) 2008-02-29
NZ510275A (en) 2003-07-25
NO20011933L (no) 2001-06-25
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
US6964780B1 (en) 2005-11-15
JP2002528408A (ja) 2002-09-03
EP1123088A1 (fr) 2001-08-16
OA11664A (en) 2005-01-07
IS5865A (is) 2001-02-27
HUP0104318A2 (hu) 2002-03-28
MXPA01004011A (es) 2003-03-10
UA67802C2 (uk) 2004-07-15
SK5192001A3 (en) 2002-09-10
KR20010075659A (ko) 2001-08-09
EE200100235A (et) 2002-08-15
CO5160262A1 (es) 2002-05-30
HK1041818A1 (zh) 2002-07-26
EP1123088B1 (fr) 2006-09-27
TR200101103T2 (tr) 2001-09-21
NO20011933D0 (no) 2001-04-19
PA8484301A1 (es) 2000-09-29
DE69933383T2 (de) 2007-02-01
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
CZ20011427A3 (cs) 2001-10-17
HRP20010285A2 (en) 2002-06-30
HUP0104318A3 (en) 2003-12-29
MY130727A (en) 2007-07-31
CA2348086A1 (fr) 2000-05-04
DE69933383D1 (de) 2006-11-09
PE20001286A1 (es) 2000-11-22
PT1123088E (pt) 2007-01-31
CN1324233A (zh) 2001-11-28
SK286473B6 (sk) 2008-11-06
CY1106239T1 (el) 2011-06-08
EA200100298A1 (ru) 2001-08-27
AU5878799A (en) 2000-05-15
PL195789B1 (pl) 2007-10-31
ID28232A (id) 2001-05-10
UY25765A1 (es) 2001-08-27
TW577756B (en) 2004-03-01
DK1123088T3 (da) 2007-01-02

Similar Documents

Publication Publication Date Title
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
TWI265808B (en) Valdecoxib compositions
EP0963200A4 (fr) Methodes et compositions visant a l'inhibition de l'angiogenese
DK0888111T3 (da) Modified-release-dosispræparat med multiple enheder
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
MA24729A1 (fr) Macrolides nouveaux.
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
TNSN04045A1 (fr) Compositions de valdecoxib a delitement intra-oral
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
MA26735A1 (fr) Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26698A1 (fr) Composition pharmaceutique concentree liquide de sertraline et procede pour sa preparation
MA27136A1 (fr) Association nouvelle.
NO990450L (no) Behandling av sinnslidelser
MA24682A1 (fr) Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant